75176-37-3

Basic information

• Product Name: Zofenoprilat
• Synonyms: zofenoprilat;(2s,4s)-1-[(2r)-2-methyl-3-sulfanyl-propanoyl]-4-phenylsulfanyl-pyrrolidine-2-carboxylic acid;(1(r*),2alpha,4alpha)-1-(3-mercapto-2-methyl-1-oxopropyl)-4-(phenylthio)-l-proline;ZofenoprilatC15H19N03S2;[1(S),4(S)]-1-(3-Mercapto-2-methyl-1-oxopropyl)-4-phenyl-thio-L-proline,;zofenoprilate;(4S)-1-[(2S)-3-Mercapto-2-methyl-1-oxopropyl]-4-(phenylthio)-L-proline;[1(R*),2a,4a]-1-(3-Mercapto-2-methyl-1-oxopropyl)-4-(phenylthio)-L-proline
• CAS NO: 75176-37-3
• Molecular Formula: C₁₅H₁₉NO₃S₂
• Molecular Weight: 325.45
• Product Categories: All Inhibitors;Inhibitors;Intermediates & Fine Chemicals;Metabolites & Impurities;MTS & Sulfhydryl Active Reagents;Pharmaceuticals
• Mol File: 75176-37-3.mol
• Article Data: 2

Chemical Properties

• Boiling Point: 646.3 °C at 760 mmHg
• Flash Point: 344.7 °C
• Appearance: /
• Density: 1.34 g/cm³
• Refractive Index: 1.658
• CAS DataBase Reference: Zofenoprilat(CAS DataBase Reference)
• NIST Chemistry Reference: Zofenoprilat(75176-37-3)
• EPA Substance Registry System: Zofenoprilat(75176-37-3)

Safety Data

• Hazardous Substances Data: 75176-37-3(Hazardous Substances Data)

Usage

Chemical Properties

White crystalline

Originator

Zofenil arginine,Menarini

Uses

The active metabolite of Zofenopril, an ACE inhibitor

Definition

ChEBI: A proline derivative that is 4-(phenylsulfanyl)-L-proline in which the amine proton is replaced by a (2S)-2-methyl-3-sulfanylpropanoyl group. The active metabolite of zofenopril.

Manufacturing Process

Sodium metal (0.85 g, 0.037 mole) is dissolved in 40 ml of absolute ethanol. To this there is added with stirring 3.7 ml (0.036 mole) of thiophenol followed by 7.5 g (0.017 mole) of N-carbobenzyloxy-trans-4-tosyloxy-L-proline, methyl ester [J. Am. Chem. Soc., 79, 191 (1957)]. After stirring for 4 h and standing overnight at room temperature, the bulk of the ethanol is removed on a rotary evaporator. The mostly solid residue is stirred with 120 ml of dichloromethane and 60 ml of water. The layers are separated (some methanol is added to help break up emulsions) and the aqueous phase is extracted with additional dichloromethane (2x60 ml). The combined organic phase are washed with 100 ml of saturated sodium chloride solution, dried (MgSO 4 ), and the solvent evaporated to give 6.5 g (100%) of N-carbobenzyloxy-cis-4-phenylthio-L- proline, methyl ester as a pale yellow viscous oil. The N-carbobenzyloxy-cis-4-phenylthio-L-proline, methyl ester (6.5 g, 0.017 mole) is dissolved in 55 ml of methanol, treated portionwise at -1° to 4°C with 13 ml (0.026 mole) of 2 N sodium hydroxide, stirred at 0°C for 1 h, and kept at room temperature for approximately 16 h. After removing about half of the solvent on a rotary evaporator, the cooled solution is diluted with 100 ml of water, washed with 60 ml of ether (wash discarded), layered over with 70 ml of ethyl acetate, stirred, cooled, and acidified with 4.8 ml of 1:1 hydrochloric acid. After separating, the aqueous phase is extracted with additional ethyl acetate (3x40 ml) and the combined organic layers are dried (MgSO 4 ) and evaporated to give 5.9 g of a light yellow viscous oil. The latter is dissolved in 30 ml of ethanol, treated with 1.9 g of cyclohexylamine in 3 ml of ethanol and diluted to 330 ml with ether. On seeding, the crystalline cyclohexylamine salt separates. The latter, after cooling for approximately 16 h, weighs 5.3 g; melting point 148-151°C. This material is combined with 1.5 g of identical product from a previous experiment, stirred with 200 ml of boiling acetonitrile, and cooled to yield 6.3 g of colorless N-carbobenzyloxy- cis-4-phenylthio-L-proline cyclohexylamine salt; melting point 152-155°C. This N-carbobenzyloxy-cis-4-phenylthio-L-proline cyclohexylamine salt is suspended in 25 ml of ethyl acetate, stirred, and treated with 25 ml of 1 N hydrochloric acid. When two clear layers are obtained, they are separated and the aqueous phase is extracted with additional ethyl acetate (3x25 ml). The combined organic layers are dried (MgSO 4 ) and the solvent evaporated to give 5.0 g (65%) of N-carbobenzyloxy-cis-4-phenylthio-L-proline as a nearly colorless, very viscous syrup.N-Carbobenzyloxy-cis-4-phenylthio-L-proline (4.9 g, 0.014 mole) is treated with 25 ml of hydrogen bromide in acetic acid (30-32%), stoppered loosely, and stirred magnetically. After 1 h the orange-yellow solution is diluted to 250 ml with ether to precipitate the product as a heavy oil which gradually crystallizes on seeding, rubbing and cooling After stirring in an ice-bath for 1 h, the material is filtered under nitrogen, washed with ether, suspended in fresh ether, cooled for approximately 16 h, and filtered again to give 3.2 g (77%) of colorless solid (cis)-4-phenylthio-L-proline hydrobromide; melting point 106-109°C.A solution of 3.0 g (0.0094 mole) of (cis)-4-phenylthio-L-proline hydrobromide in 25 ml of water is stirred, cooled to 5°C and 15 ml of 20% sodium carbonate are added. This mixture is treated with 2.0 g (0.011 mole) of D-3- acetylthio-2-methylpropionyl chloride in 5 ml of ether during the course of 10 min with the intermittent addition of 3.0 g of sodium carbonate to maintain the pH at 8.0 to 8.4). The mixture is stirred in the ice-bath for an additional hour, 25 ml of water are added and then a solution of 5 ml of concentrated hydrochloric acid in 25 ml of water. The strongly acid solution is saturated with sodium chloride and extracted with 50 ml of ethyl acetate (four times). The organic phases are combined, dried, filtered and solvent evaporated to give 3.8 g of a pale yellow viscous oil. The dicyclohexylamine salt following trituration with 15 ml of acetonitrile one obtains 2.4 g of colorless solid 1-[D- 3-(acetylthio)-2-methyl-1-oxopropyl]-cis-4-phenylthio-L-proline dicyclohexylamine salt; melting point 184-186°C.

Therapeutic Function

Antihypertensive

InChI:InChI=1/C22H23NO4S2/c1-15(14-28-22(27)16-8-4-2-5-9-16)20(24)23-13-18(12-19(23)21(25)26)29-17-10-6-3-7-11-17/h2-11,15,18-19H,12-14H2,1H3,(H,25,26)/t15-,18-,19-/m0/s1

Upstream product

• 113949-52-3 (4S)-1-[(S)-3-benzoylthio-2-methylpropanoyl]-4-phenylthio-L-proline methyl ester 
• 81653-77-2 (S)-4-phenylthio-L-proline 
• 51-35-4 4R-4-hydroxyproline 
• 81814-84-8 (1S,4R)-1-<3-(benzoylthio)-2-methyl-1-oxopropyl>-4-hydroxy-L-proline 
• 681144-92-3 (4S)-1-(2-methylpropenoyl)-4-phenylthio-L-proline methyl ester 
• 126111-05-5 4-phenylsulfanylpyrrolidine-2-carboxylic acid methyl ester 
• 80586-33-0 (1S,4R)-1-<3-(benzoylthio)-2-methyl-1-oxopropyl>-4-hydroxy-L-proline methyl ester 

Relevant articles and documents

11C-Radiosynthesis and preliminary human evaluation of the disposition of the ACE inhibitor [11C]zofenoprilat

(4S)-1-[(S)-3-Mercapto-2-methylpropanoyl]-4-phenylthio-L-proline (Zofenoprilat, 2), the active metabolite of the potent ACE inhibitor Zofenopril Calcium (1), was labelled with carbon-11 (t1/2=20.4 min) to evaluate its pharmacokinetics behaviour in human body using Positron Emission Tomography (PET). [11C]2 labelling procedures were based on the use of immobilized Grignard reagent and the acylation of (S)-4-phenylthio-L-proline methyl ester (5) with 11C-labelled methacryloyl chloride, followed by a Michael addition with thiobenzoic acid. The radiochemical yield was 5-10% (EOB, decay corrected) and specific radioactivity ranged from 0.5 to 1.5 Ci/μmol (18.5-55.5 GBq/μmol). Preliminary in vivo human evaluation of [11C]2 showed that the drug accumulates in organs which express high levels of ACE, like lungs and kidneys, and in organs involved in drug metabolism such as the liver and gall bladder. Results of the distribution of [11C]2 showed a measurable concentration of the drug in the target tissues such as the kidney and to a minor extent, the heart, where it can afford organ protection.